niacin and alpha-Lipoprotein Deficiency Disease, Familial studies

Niacin: A water-soluble vitamin of the B complex occurring in various animal and plant tissues. It is required by the body for the formation of coenzymes NAD and NADP. It has PELLAGRA-curative, vasodilating, and antilipemic properties.
vitamin B3 : Any member of a group of vitamers that belong to the chemical structural class called pyridines that exhibit biological activity against vitamin B3 deficiency. Vitamin B3 deficiency causes a condition known as pellagra whose symptoms include depression, dermatitis and diarrhea. The vitamers include nicotinic acid and nicotinamide (and their ionized and salt forms).
nicotinic acid : A pyridinemonocarboxylic acid that is pyridine in which the hydrogen at position 3 is replaced by a carboxy group.

Research Excerpts

Excerpt	Relevance	Reference
"To determine the effect of extended release (ER) niacin on endothelial and vascular function assessed by brachial flow-mediated dilatation (FMD), peak hyperemic velocity (VTiRH) and pulse arterial tonometry (PAT) in patients with established coronary artery disease (CAD), already treated with high dose statins."	9.17	Niacin improves lipid profile but not endothelial function in patients with coronary artery disease on high dose statin therapy. ( Anderson, TJ; Hillard, D; Hubacek, J; Philpott, AC; Sun, YC, 2013)
"To determine the effect of extended release (ER) niacin on endothelial and vascular function assessed by brachial flow-mediated dilatation (FMD), peak hyperemic velocity (VTiRH) and pulse arterial tonometry (PAT) in patients with established coronary artery disease (CAD), already treated with high dose statins."	5.17	Niacin improves lipid profile but not endothelial function in patients with coronary artery disease on high dose statin therapy. ( Anderson, TJ; Hillard, D; Hubacek, J; Philpott, AC; Sun, YC, 2013)
"Niacin has been reported to lower apoB and Lp(a) and to raise apoA-1."	2.78	Relationship of apolipoproteins A-1 and B, and lipoprotein(a) to cardiovascular outcomes: the AIM-HIGH trial (Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglyceride and Impact on Global Health Outcomes). ( Albers, JJ; Kashyap, ML; Kwiterovich, PO; Marcovina, SM; O'Brien, KD; Robinson, JG; Slee, A; Xu, P, 2013)
"Niacin and fibrates have been shown in clinical trials to be effective as adjunctive therapy for these lipid abnormalities."	1.35	Niacin and fibrate use among patients with high triglycerides and low high-density lipoprotein cholesterol. ( Laitinen, D; Sullivan, JM; Toth, PP; Zarotsky, V, 2009)

Research

Studies (5)

Authors

Clinical Trials (2)

Trial Overview

Trial Outcomes

Cardiovascular Mortality

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (20.00)	29.6817
2010's	4 (80.00)	24.3611
2020's	0 (0.00)	2.80

Authors	Studies
Albers, JJ	1
Slee, A	1
O'Brien, KD	1
Robinson, JG	1
Kashyap, ML	1
Kwiterovich, PO	1
Xu, P	1
Marcovina, SM	1
Santos-Gallego, CG	1
Rosenson, RS	1
Figueroa, C	1
Droppelmann, K	1
Quiñones, V	1
Amigo, L	1
Mendoza, C	1
Serrano, V	1
Véjar, M	1
Maiz, A	1
Rigotti, A	1
Toth, PP	1
Zarotsky, V	1
Sullivan, JM	1
Laitinen, D	1
Philpott, AC	1
Hubacek, J	1
Sun, YC	1
Hillard, D	1
Anderson, TJ	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
AIM HIGH: Niacin Plus Statin to Prevent Vascular Events[NCT00120289]	Phase 3	3,414 participants (Actual)	Interventional	2005-09-30	Terminated (stopped due to AIM-HIGH was stopped on the recommendation of the DSMB because of lack of efficacy of niacin in preventing primary outcome events.)
HDL Modulation and Endothelial Function[NCT00150722]	Phase 3	75 participants (Actual)	Interventional	2005-09-30	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

(NCT00120289)
Timeframe: Time to first event measured from date of randomization through last follow-up visit (common termination), for an average of 36 months follow-up, maximum 66 months.

Composite End Point of CHD Death, Nonfatal MI, Ischemic Stroke, Hospitalization for Non-ST Segment Elevation Acute Coronary Syndrome (ACS), or Symptom-driven Coronary or Cerebral Revascularization

Intervention	participants (Number)
ERN + Simvastatin	45
Placebo + Simvastatin	38

(NCT00120289)
Timeframe: Time to first event measured from date of randomization through last follow-up visit (common termination) for an average of 36 months follow-up, maximum 66 months.

Composite Endpoint of CHD Death, Non-fatal MI, High-risk ACS or Ischemic Stroke

Intervention	participants (Number)
ERN + Simvastatin	282
Placebo + Simvastatin	274

(NCT00120289)
Timeframe: Time to first event measured from date of randomization through last follow-up visit (common termination) for an average of 36 months follow-up, maximum 66 months

Composite Endpoint of CHD Death, Non-fatal MI, or Ischemic Stroke

Intervention	participants (Number)
ERN + Simvastatin	171
Placebo + Simvastatin	158

(NCT00120289)
Timeframe: Time to first event measured from date of randomization through last follow-up visit (common termination) for an average of 36 months follow-up, maximum 66 months

Reviews

1 review available for niacin and alpha-Lipoprotein Deficiency Disease, Familial

Trials

2 trials available for niacin and alpha-Lipoprotein Deficiency Disease, Familial

Other Studies

2 other studies available for niacin and alpha-Lipoprotein Deficiency Disease, Familial

Article	Year
[Nicotinic acid increases cellular transport of high density lipoprotein cholesterol in patients with hypoalphalipoproteinemia]. Revista medica de Chile, 2015, Volume: 143, Issue:9 Topics: Aged; Biological Transport; Cholesterol, HDL; Female; Humans; Hypoalphalipoproteinemias; Hypolipidem	2015
Niacin and fibrate use among patients with high triglycerides and low high-density lipoprotein cholesterol. Current medical research and opinion, 2009, Volume: 25, Issue:6 Topics: Adult; Cardiovascular Diseases; Cholesterol, HDL; Clofibric Acid; Drug Combinations; Female; Humans;	2009